罗莫单抗治疗原发性胆汁性胆管炎的疗效，推荐剂量为体重不足患者的一半

IF 2.1 Q3 ENDOCRINOLOGY & METABOLISM Bone Reports Pub Date : 2024-01-11 DOI:10.1016/j.bonr.2024.101736

Bhanvi Ramchandani , Faryal Sardar Mirza

{"title":"罗莫单抗治疗原发性胆汁性胆管炎的疗效，推荐剂量为体重不足患者的一半","authors":"Bhanvi Ramchandani , Faryal Sardar Mirza","doi":"10.1016/j.bonr.2024.101736","DOIUrl":null,"url":null,"abstract":"<div><p>Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe osteoporosis and primary biliary cholangitis (PBC). Using half dose RSB (approximately 3 mg/kg RSB), she demonstrated significant improvement in lumbar spine BMD, paralleling the results of phase III trials. This case highlights the effectiveness of RSB in a patient with concomitant PBC, in addition to its effectiveness at half the recommended dose in an underweight patient.</p></div>","PeriodicalId":9043,"journal":{"name":"Bone Reports","volume":"20 ","pages":"Article 101736"},"PeriodicalIF":2.1000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2352187224000032/pdfft?md5=2e88386e312f8b2e91b70067bc5ebc14&pid=1-s2.0-S2352187224000032-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient\",\"authors\":\"Bhanvi Ramchandani , Faryal Sardar Mirza\",\"doi\":\"10.1016/j.bonr.2024.101736\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe osteoporosis and primary biliary cholangitis (PBC). Using half dose RSB (approximately 3 mg/kg RSB), she demonstrated significant improvement in lumbar spine BMD, paralleling the results of phase III trials. This case highlights the effectiveness of RSB in a patient with concomitant PBC, in addition to its effectiveness at half the recommended dose in an underweight patient.</p></div>\",\"PeriodicalId\":9043,\"journal\":{\"name\":\"Bone Reports\",\"volume\":\"20 \",\"pages\":\"Article 101736\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2352187224000032/pdfft?md5=2e88386e312f8b2e91b70067bc5ebc14&pid=1-s2.0-S2352187224000032-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bone Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2352187224000032\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bone Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352187224000032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

Romosozumab (RSB) 是一种硬骨生成素单克隆抗体，获准用于治疗绝经后高骨折风险骨质疏松症。它每月皮下注射 210 毫克，疗程为 12 个月。我们报告了一位体重不足、患有严重骨质疏松症和原发性胆汁性胆管炎（PBC）的患者对半量标准剂量 RSB 的反应。使用半量 RSB（约 3 毫克/千克 RSB）后，她的腰椎 BMD 有了显著改善，与 III 期试验的结果一致。本病例强调了 RSB 对合并有 PBC 的患者的有效性，以及对体重不足的患者使用推荐剂量一半的 RSB 的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Effectiveness of romosozumab in primary biliary cholangitis at half the recommended dose in an underweight patient

Romosozumab (RSB) is a monoclonal antibody to sclerostin that is approved for post-menopausal osteoporosis at high fracture risk. It is administered as a monthly 210 mg subcutaneous injection for 12 months. We report the response to half the standard dose of RSB in an underweight patient with severe osteoporosis and primary biliary cholangitis (PBC). Using half dose RSB (approximately 3 mg/kg RSB), she demonstrated significant improvement in lumbar spine BMD, paralleling the results of phase III trials. This case highlights the effectiveness of RSB in a patient with concomitant PBC, in addition to its effectiveness at half the recommended dose in an underweight patient.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Bone Reports Medicine-Orthopedics and Sports Medicine

CiteScore

4.30

自引率

4.00%

发文量

444

审稿时长

57 days

期刊介绍： Bone Reports is an interdisciplinary forum for the rapid publication of Original Research Articles and Case Reports across basic, translational and clinical aspects of bone and mineral metabolism. The journal publishes papers that are scientifically sound, with the peer review process focused principally on verifying sound methodologies, and correct data analysis and interpretation. We welcome studies either replicating or failing to replicate a previous study, and null findings. We fulfil a critical and current need to enhance research by publishing reproducibility studies and null findings.